Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Seckinger, A. (Anja) | - |
dc.creator | Delgado, J.A. (Jose Antonio) | - |
dc.creator | Moser, S. (Samuel) | - |
dc.creator | Moreno, L. (Laura) | - |
dc.creator | Neuber, B. (Brigitte) | - |
dc.creator | Grab, A. (Anna) | - |
dc.creator | Lipp, S. (Susanne) | - |
dc.creator | Merino, J. (Juana) | - |
dc.creator | Prosper-Cardoso, F. (Felipe) | - |
dc.creator | Emde, M. (Martina) | - |
dc.creator | Delon, C. (Camille) | - |
dc.creator | Latzko, M. (Melanie) | - |
dc.creator | Gianotti, R. (Reto) | - |
dc.creator | Lüoend, R. (Remo) | - |
dc.creator | Murr, R. (Ramona) | - |
dc.creator | Hosse, R.J. (Ralf J.) | - |
dc.creator | Harnisch, L.J. (Lydia Jasmin) | - |
dc.creator | Bacac, M. (Marina) | - |
dc.creator | Fauti, T. (Tanja) | - |
dc.creator | Klein, C. (Christian) | - |
dc.creator | Zabaleta, A. (Aintzane) | - |
dc.creator | Hillengass, J. (Jens) | - |
dc.creator | Cavalcanti-Adam, E.A. (Elisabetta Ada) | - |
dc.creator | Ho, A.D. (Anthony D.) | - |
dc.creator | Hundemer, M. (Michael) | - |
dc.creator | San-Miguel, J.F. (Jesús F.) | - |
dc.creator | Strein, K. (Klaus) | - |
dc.creator | Umaña, P. (Pablo) | - |
dc.creator | Hose, D. (Dirk) | - |
dc.creator | Paiva, B. (Bruno) | - |
dc.creator | Vu, M.D. (Minh Diem) | - |
dc.date.accessioned | 2018-05-09T07:53:49Z | - |
dc.date.available | 2018-05-09T07:53:49Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Seckinger, A. (Anja); Delgado, J.A. (Jose Antonio); Moser, S. (Samuel); et al. "Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment". Cell Reports. 31, 2017, 396 - 410 | es |
dc.identifier.issn | 2211-1247 | - |
dc.identifier.uri | https://hdl.handle.net/10171/52174 | - |
dc.description.abstract | We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myeloma cell crosslinking, followed by CD4+/CD8+ T cell activation, and secretion of interferon-γ, granzyme B, and perforin. This effect is CD4 and CD8 T cell mediated. EM801 induced, at nanomolar concentrations, myeloma cell death by autologous T cells in 34 of 43 bone marrow aspirates, including those from high-risk patients and patients after multiple lines of treatment, tumor regression in six of nine mice in a myeloma xenograft model, and depletion of BCMA+ cells in cynomolgus monkeys. Pharmacokinetics and pharmacodynamics indicate weekly intravenous/subcutaneous administration. | es_ES |
dc.description.sponsorship | This work was supported by EngMab AG, the German Federal Ministry of Education (‘‘CLIOMMICS’’ [01ZX1309], ‘‘CAMPSIMM’’ [01ES1103]), the Deutsche Forschungsgemeinschaft (SFB/ TRR79; TP B1, B12, M9), the Cooperative Research Thematic Network grants RD12/0036/0058 of the Red de Cancer (Cancer Network of Excellence), Instituto de Salud Carlos III, Spain, (Sara Borrell: CD13/00340), and Asociacio´ n Espan ˜ ola Contra el Ca´ ncer (GCB120981SAN), and the Black Swan Research Initiative from the International Myeloma Foundation. We declare research funding from EngMab AG. K.S. and M.D.V. are employees of EngMab AG. S.M., C.D., M.L., R.G., R.L., R.M., R.J.H., L.J.H., M.B., T.F., C.K., and P.U. are Hoffman-La Roche employees. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/ERC/680200MYELOMANEXT | - |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud::Hematología | es_ES |
dc.subject | Multiple myeloma | es_ES |
dc.subject | BCMA | es_ES |
dc.subject | Immunotherapy | es_ES |
dc.subject | T cell bispecific antibody | es_ES |
dc.subject | Redirected cell killing | es_ES |
dc.title | Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S1535610817300168?via%3Dihub | es_ES |
dc.description.note | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | es_ES |
dc.identifier.doi | 10.1016/j.ccell.2017.02.002 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.